QQQ   303.59 (-0.85%)
AAPL   151.73 (-1.79%)
MSFT   256.77 (-0.61%)
META   186.06 (-0.25%)
GOOGL   102.90 (-1.79%)
AMZN   102.18 (-1.17%)
TSLA   194.76 (+2.52%)
NVDA   210.89 (-0.05%)
NIO   10.93 (-2.32%)
BABA   105.45 (-0.83%)
AMD   83.68 (-2.80%)
T   19.58 (-1.26%)
F   13.14 (-0.68%)
MU   59.98 (-3.89%)
CGC   2.95 (+1.03%)
GE   82.35 (+0.48%)
DIS   109.87 (-0.76%)
AMC   6.80 (+11.84%)
PFE   43.76 (-0.68%)
PYPL   82.33 (-3.73%)
NFLX   361.48 (-1.21%)
QQQ   303.59 (-0.85%)
AAPL   151.73 (-1.79%)
MSFT   256.77 (-0.61%)
META   186.06 (-0.25%)
GOOGL   102.90 (-1.79%)
AMZN   102.18 (-1.17%)
TSLA   194.76 (+2.52%)
NVDA   210.89 (-0.05%)
NIO   10.93 (-2.32%)
BABA   105.45 (-0.83%)
AMD   83.68 (-2.80%)
T   19.58 (-1.26%)
F   13.14 (-0.68%)
MU   59.98 (-3.89%)
CGC   2.95 (+1.03%)
GE   82.35 (+0.48%)
DIS   109.87 (-0.76%)
AMC   6.80 (+11.84%)
PFE   43.76 (-0.68%)
PYPL   82.33 (-3.73%)
NFLX   361.48 (-1.21%)
QQQ   303.59 (-0.85%)
AAPL   151.73 (-1.79%)
MSFT   256.77 (-0.61%)
META   186.06 (-0.25%)
GOOGL   102.90 (-1.79%)
AMZN   102.18 (-1.17%)
TSLA   194.76 (+2.52%)
NVDA   210.89 (-0.05%)
NIO   10.93 (-2.32%)
BABA   105.45 (-0.83%)
AMD   83.68 (-2.80%)
T   19.58 (-1.26%)
F   13.14 (-0.68%)
MU   59.98 (-3.89%)
CGC   2.95 (+1.03%)
GE   82.35 (+0.48%)
DIS   109.87 (-0.76%)
AMC   6.80 (+11.84%)
PFE   43.76 (-0.68%)
PYPL   82.33 (-3.73%)
NFLX   361.48 (-1.21%)
QQQ   303.59 (-0.85%)
AAPL   151.73 (-1.79%)
MSFT   256.77 (-0.61%)
META   186.06 (-0.25%)
GOOGL   102.90 (-1.79%)
AMZN   102.18 (-1.17%)
TSLA   194.76 (+2.52%)
NVDA   210.89 (-0.05%)
NIO   10.93 (-2.32%)
BABA   105.45 (-0.83%)
AMD   83.68 (-2.80%)
T   19.58 (-1.26%)
F   13.14 (-0.68%)
MU   59.98 (-3.89%)
CGC   2.95 (+1.03%)
GE   82.35 (+0.48%)
DIS   109.87 (-0.76%)
AMC   6.80 (+11.84%)
PFE   43.76 (-0.68%)
PYPL   82.33 (-3.73%)
NFLX   361.48 (-1.21%)
NASDAQ:MRVI

Maravai LifeSciences - MRVI Stock Forecast, Price & News

$14.48
-0.40 (-2.69%)
(As of 02/6/2023 12:00 AM ET)
Add
Compare
Today's Range
$14.44
$14.83
50-Day Range
$12.50
$15.50
52-Week Range
$12.16
$41.82
Volume
1.33 million shs
Average Volume
1.44 million shs
Market Capitalization
$3.70 billion
P/E Ratio
8.09
Dividend Yield
N/A
Price Target
$23.00

Maravai LifeSciences MarketRank™ Forecast

Analyst Rating
Moderate Buy
2.75 Rating Score
Upside/​Downside
58.8% Upside
$23.00 Price Target
Short Interest
Healthy
4.73% of Float Sold Short
Dividend Strength
N/A
Sustainability
-1.23
Upright™ Environmental Score
News Sentiment
0.84mentions of Maravai LifeSciences in the last 14 days
Based on 4 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
-81.01%
From $1.79 to $0.34 Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.46 out of 5 stars

Medical Sector

151st out of 1,027 stocks

Pharmaceutical Preparations Industry

62nd out of 500 stocks

MRVI stock logo

About Maravai LifeSciences (NASDAQ:MRVI) Stock

Maravai LifeSciences Holdings, Inc., a life sciences company, provides products to enable the development of drug therapies, diagnostics, novel vaccines, and support research on human diseases in the United States and internationally. The company's products address the key phases of biopharmaceutical development and include nucleic acids for diagnostic and therapeutic applications, antibody-based products to detect impurities during the production of biopharmaceutical products, and products to detect the expression of proteins in tissues of various species. It operates in two segments, Nucleic Acid Production and Biologics Safety Testing. The Nucleic Acid Production segment manufactures and sells products for use in the fields of gene therapy, nucleoside chemistry, oligonucleotide therapy, and molecular diagnostics, including reagents used in the chemical synthesis, modification, labelling, and purification of deoxyribonucleic acid (DNA) and ribonucleic acid (RNA). This segment also offers messenger RNA, oligonucleotides, and oligonucleotide building blocks, as well as plasmid DNA and CleanCap capping technology. The Biologics Safety Testing segment sells analytical products for use in biologic manufacturing process development, including custom product-specific development antibody and assay development services. This segment also provides HCP ELISA kits, other bioprocess impurity and contaminant ELISA kits, ancillary reagents, and custom services. The company serves biopharmaceutical companies, and other biopharmaceutical and life sciences research companies; and academic research institutions and in vitro diagnostics companies. Maravai LifeSciences Holdings, Inc. was incorporated in 2020 and is headquartered in San Diego, California.

Receive MRVI Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Maravai LifeSciences and its competitors with MarketBeat's FREE daily newsletter.

MRVI Stock News Headlines

A gold storm is coming…
“We are in the early stages of a mania – the calm before the storm.”...
3 Biopharma Stocks That Could Help Make You a Fortune
A gold storm is coming…
“We are in the early stages of a mania – the calm before the storm.”...
Maravai LifeSciences appoints intemin CEO
What 6 Analyst Ratings Have To Say About Maravai LifeSciences
Where Maravai LifeSciences Stands With Analysts
Analyst Ratings for Maravai LifeSciences
This Pandemic Star Is Embroiled in CEO Drama
Maravai LifeSciences: Establishing The Diagnosis
See More Headlines
Receive MRVI Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Maravai LifeSciences and its competitors with MarketBeat's FREE daily newsletter.

MRVI Company Calendar

Last Earnings
11/10/2021
Today
2/06/2023
Next Earnings (Confirmed)
2/22/2023
Fiscal Year End
12/31/2023

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:MRVI
Fax
N/A
Employees
470
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$23.00
High Stock Price Forecast
$32.00
Low Stock Price Forecast
$16.00
Forecasted Upside/Downside
+58.8%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.75
Research Coverage
8 Analysts

Profitability

Net Income
$182.04 million
Pretax Margin
66.20%

Debt

Sales & Book Value

Annual Sales
$906.73 million
Cash Flow
$1.68 per share
Book Value
$2.14 per share

Miscellaneous

Free Float
254,926,000
Market Cap
$3.70 billion
Optionable
Not Optionable
Beta
-0.22

Key Executives

  • Mr. Carl W. Hull (Age 64)
    Co-Founder and Exec. Chairman & Interim CEO
    Comp: $1.78M
  • Mr. Kevin M. Herde (Age 51)
    Exec. VP & CFO
    Comp: $841.6k
  • Mr. Kurt Oreshack (Age 42)
    Exec. VP, Gen. Counsel & Sec.
    Comp: $701.4k
  • Ms. Christine Dolan (Age 55)
    Chief Operating Officer of Biologics Safety Testing
    Comp: $844.67k
  • Mr. Brian Neel (Age 47)
    Chief Operating Officer of Nucleic Acid Production
    Comp: $797.38k
  • Dr. Peter Michael Leddy Ph.D. (Age 60)
    Exec. VP & Chief Admin. Officer
  • Ms. Debra Hart
    Sr. Director of Investor Relations
  • Ms. Doreen Pippen
    VP of Marketing
  • Mr. William Martin III
    Pres of Biologics Safety Testing













MRVI Stock - Frequently Asked Questions

Should I buy or sell Maravai LifeSciences stock right now?

8 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Maravai LifeSciences in the last twelve months. There are currently 2 hold ratings and 6 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" MRVI shares.
View MRVI analyst ratings
or view top-rated stocks.

What is Maravai LifeSciences' stock price forecast for 2023?

8 equities research analysts have issued 12-month price objectives for Maravai LifeSciences' shares. Their MRVI share price forecasts range from $16.00 to $32.00. On average, they predict the company's share price to reach $23.00 in the next twelve months. This suggests a possible upside of 56.4% from the stock's current price.
View analysts price targets for MRVI
or view top-rated stocks among Wall Street analysts.

How have MRVI shares performed in 2023?

Maravai LifeSciences' stock was trading at $14.31 on January 1st, 2023. Since then, MRVI shares have increased by 2.8% and is now trading at $14.71.
View the best growth stocks for 2023 here
.

When is Maravai LifeSciences' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Wednesday, February 22nd 2023.
View our MRVI earnings forecast
.

How can I listen to Maravai LifeSciences' earnings call?

Maravai LifeSciences will be holding an earnings conference call on Wednesday, February 22nd at 5:00 PM Eastern. Interested parties can register for or listen to the call using this link.

How were Maravai LifeSciences' earnings last quarter?

Maravai LifeSciences Holdings, Inc. (NASDAQ:MRVI) issued its quarterly earnings results on Wednesday, November, 10th. The company reported $0.44 earnings per share for the quarter, beating analysts' consensus estimates of $0.35 by $0.09. The firm earned $204.81 million during the quarter, compared to the consensus estimate of $199.68 million. Maravai LifeSciences had a trailing twelve-month return on equity of 69.19% and a net margin of 26.29%.

What guidance has Maravai LifeSciences issued on next quarter's earnings?

Maravai LifeSciences issued an update on its FY 2022 earnings guidance on Wednesday, November, 9th. The company provided EPS guidance of $1.76-$1.80 for the period, compared to the consensus estimate of $1.76. The company issued revenue guidance of $880.00 million-$890.00 million, compared to the consensus revenue estimate of $889.97 million.

When did Maravai LifeSciences IPO?

(MRVI) raised $1.3 billion in an initial public offering (IPO) on Friday, November 20th 2020. The company issued 50,000,000 shares at a price of $24.00-$27.00 per share. Morgan Stanley, Jefferies and Goldman Sachs served as the underwriters for the IPO and BofA Securities, Credit Suisse, UBS Investment Bank, Baird, William Blair, Stifel, Keybanc Securities, Academy Securities, Loop Capital Markets, Penserra Securities and Tigress Financial Partners were co-managers.

What is Maravai LifeSciences' stock symbol?

Maravai LifeSciences trades on the NASDAQ under the ticker symbol "MRVI."

Who are Maravai LifeSciences' major shareholders?

Maravai LifeSciences' stock is owned by a number of retail and institutional investors. Top institutional shareholders include Vaughan Nelson Investment Management L.P. (0.49%), Curi Wealth Management LLC (0.36%), Natixis Advisors L.P. (0.18%), State of Alaska Department of Revenue (0.15%), Bank Julius Baer & Co. Ltd Zurich (0.09%) and New York State Common Retirement Fund (0.06%).

How do I buy shares of Maravai LifeSciences?

Shares of MRVI stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Maravai LifeSciences' stock price today?

One share of MRVI stock can currently be purchased for approximately $14.71.

How much money does Maravai LifeSciences make?

Maravai LifeSciences (NASDAQ:MRVI) has a market capitalization of $3.75 billion and generates $906.73 million in revenue each year. The company earns $182.04 million in net income (profit) each year or $1.79 on an earnings per share basis.

How many employees does Maravai LifeSciences have?

The company employs 470 workers across the globe.

How can I contact Maravai LifeSciences?

Maravai LifeSciences' mailing address is 10770 WATERIDGE CIRCLE SUITE 200, SAN DIEGO CA, 92121. The official website for the company is www.maravai.com. The company can be reached via phone at 858-546-0004 or via email at ir@maravai.com.

This page (NASDAQ:MRVI) was last updated on 2/6/2023 by MarketBeat.com Staff